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mM CaCl2, 1.2 mM MgSO4, and 32.3 mM Hepes, pH 7.4, 2 mM glucose, 20 mg/ml 
BSA, and 200 nM adenosine; Hepes, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid; BSA, bovine serum albumin; SDS, sodium dodecylsulphate 
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Abstract 
   Recently, we have shown that protein kinase C (PKC) activated by phorbol 
12-myristate 13-acetate (PMA) attenuates the β1-adrenergic receptor (β1-AR)-mediated 
lipolysis in rat adipocytes.  Stimulation of cells by insulin, angiotensin II, and α1-AR 
agonist is known to cause activation of PKC.  In this study, we found that lipolysis 
induced by the β1-AR agonist dobutamine is decreased and is no longer inhibited by 
PMA in adipocytes that have been treated with 20 nM insulin for 30 min followed by 
washing out insulin.  Such effects on lipolysis were not found after pretreatment with 
angiotensin II and α1-AR agonists.  The rate of lipolysis in the insulin-treated cells was 
normalized by the PKCα- and β-specific inhibitor Gö 6976 and PKCβ-specific inhibitor 
LY 333531.  In the insulin-treated cells, wortmannin increased lipolysis and recovered 
the lipolysis-attenuating effect of PMA.  Western blot analysis revealed that insulin 
slightly increases membrane-bound PKCα, βI, and δ , and wortmannin decreases PKCβI, 
βII, and δ in the membrane fraction.  These results indicate that stimulation of insulin 
receptor induces a sustained activation of PKC-dependent antilipolysis in rat adipocytes.     
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1. Introduction 
 
   Adipose tissues have important functions in the regulation of energy balance.  
Adipocytes store excess energy supply as triglyceride droplets, resulting in the 
development of obesity.  During fasting and exercise, triglycerides stored in the cells 
are hydrolyzed producing glycerol and free fatty acids, which are important oxidative 
fuels for other tissues such as liver, skeletal muscle, kidney, and the myocardium.  
Different hormones govern the use of energy in the triglyceride depots (1, 2). 
   Rat adipocytes contain three β-adrenergic receptor (β-AR) subtypes: β1, β2, and β3.  
The three β-ARs are coupled with Gs protein and transmit an activation signal to 
adenylylcyclase, leading to an increase in cAMP.  The resulting activation of protein 
kinase A (PKA) mediates activation of hormone-sensitive lipase (HSL), which 
hydrolyzes triglycerides stored in the cells (1, 2).  The fact that the protein level of 
β2-AR is extremely low (3) and that lipolysis stimulated by norepinephrine and 
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isoproterenol is not significantly affected by a β2-AR antagonist ICI 118551 (4) indicate 
a very minor role of the β2-AR signaling for lipolysis in rat adipocytes.  β3-AR may 
represent the physiological receptor for high norepinephrine concentrations (100 nM), 
attained by sympathetic activity near adipose tissues in conditions such as fasting and 
cold exposure (5, 6).  In rat adipocytes, norepinephrine at concentrations usually found 
in the circulation (1−25 nM) stimulates mainly the high-affinity β1-AR and thereby 
induces lipolysis (5).  In humans, circulating catecholamine stimulates the β1- and 
β2-ARs, which are critical determinants for the rate of lipolysis induced by submaximal 
exercise in subcutaneous adipose tissue (7) and lipolysis in response to insulin-induced 
hypoglycemia in skeletal muscle (8). 
   The rate of lipolysis is regulated not only by lipolytic hormones but also by 
antilipolytic hormones.  Insulin is the most potent antilipolytic hormone in adipose 
tissues.  It inhibits the activity of HSL by decreasing the cAMP level through 
phosphorylation and activation of phosphodiesterase 3B (PDE3B) (1).  PDE3B 
stimulation by insulin requires the activities of phosphatidylinositol 3-kinase (PI3K) and 
protein kinase B (PKB) (1, 9, 10).  Lipolysis is also inhibited by the activities of 
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α2-AR and adenosine receptor that couple to Gi protein and inhibit adenylylcyclase, and 
by other activities of different effector molecules (1, 2). 
   Using rat adipocytes, we have shown that phorbol 12-myristate 13-acetate (PMA) 
attenuates lipolysis induced by submaximally stimulating concentrations of 
isoproterenol and norepinephrine (4).  The decrease in lipolysis by PMA may be due to 
specific inhibition of the β1-AR system by the activity of protein kinase C (PKC).  In 
this study, we attempted to characterize the signaling pathway of PKC-dependent 
antilipolysis in rat adipocytes.  It was found that stimulation of insulin receptor 
substitutes for the action of PMA.  The effect of insulin on lipolysis was blocked by 
PKC inhibitors and wortmannin.   
 
2. Materials and methods 
 
2.1. Materials 
   The β-AR agonists, isoproterenol and dobutamine, and the β1-AR antagonist, CGP 
20712A, were purchased from Sigma (St. Louis, USA).  Angiotensin II, phenylephrine, 
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and methoxamine were from Wako Pure Chemical Industries (Osaka, Japan).  The 
PKC inhibitors, Gö 6976 and LY 333531, were from Calbiochem (Darmstadt, Germany) 
and Alexis (San Diego, USA), respectively.  PMA, wortmannin, and protease inhibitor 
cocktail were from Sigma.  The rabbit anti-peptide antibodies recognizing PKCα, βI, 
and βII were purchased from Santa Cruz Biotechnologies (Santa Cruz, USA) and the 
rabbit anti-peptide antibodies to PKCδ, ε, and ζ were from Sigma. 
 
2.2. Animals and adipocyte preparation 
   Male rats of the Charles River CD strain weighing 200−240 g (7 weeks old) were 
used.  Animals were fed a standard commercial diet ad libitum and allowed free access 
to water.  The light cycle was 08:00−20:00.  Isolated adipocytes were prepared from 
the epididymal fat pads by the method previously described (4).  After collagenase 
digestion, cells were washed, suspended in Dulbecco’s modified Eagle’s medium 
supplemented with 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (Hepes), 
pH 7.4, 20 mg/ml bovine serum albumin (BSA), and 200 nM adenosine, and incubated 
at 37ºC for 4 h with gentle agitation.  If necessary, cells were treated with insulin for 
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the final 30 min of a 4-h-incubation.  Then, cells were washed with a buffered solution 
containing 119 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 2.6 mM CaCl2, 1.2 mM 
MgSO4, and 32.3 mM Hepes, pH 7.4, 2 mM glucose, 20 mg/ml BSA, and 200 nM 
adenosine (buffer A).  After being washed, the volume of packed adipocytes was 
determined. 
 
2.3. Lipolysis and glycerol measurement 
   The packed adipocytes were diluted 10-fold with buffer A, and incubated at 37ºC for 
20 min in the presence of pharmacological agents.  The concentration of glycerol in 
the incubation mixture was measured to determine the rate of lipolysis.  Lipolysis, as 
assessed by glycerol release, linearly increased for at least 40 min (11). 
 
2.4. Western blot analysis 
   Adipocytes were washed three times with a buffered solution containing 10 mM Tris, 
pH 7.4, 0.15 M NaCl, 1 mM EDTA, 1 mM EGTA, and 0.5% protease inhibitor cocktail.  
Then, cells were processed for separation of the cytosol and membrane fractions as 
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described previously (4).   
   The membrane fraction from adipocytes was mixed with the sample-loading buffer, 
and subjected to sodium dodecylsulphate (SDS)-polyacrylamide gel electrophoresis 
followed by electrotransfer of protein onto a polyvinylidene difluoride membrane (4).  
After incubation of the membrane with the primary and secondary antibodies, 
immunoreactive bands were detected by ECL Plus (Amersham, UK).  Samples that 
were compared from each experiment were analyzed on the same immunoblot, and 
relative changes in the density of the bands were determined by scanning densitometry.  
 
2.5. Statistics    
   Each experiment was performed in duplicates and repeated three times or more.  
Results were mean values ± SEM.  In some cases, data were expressed as the 
percentage of the activity in control cells (taken as 100%).  If necessary, data were 
examined by Student’s t test to evaluate the statistical significance. 
 
3. Results 
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3.1. Effects of insulin, angiotensin II, and α1-AR agonist on the lipolysis-attenuating 
effect of PMA  
   Rat adipocytes possess a PKC-dependent signaling pathway for antilipolysis (4).  
To explore the mechanism of PKC signaling, adipocytes were treated with insulin, 
angiotensin II, and α1-AR agonist, which are known to activate the PKC pathway (2, 
12−17).  Adipocytes were treated with 20 nM insulin for 30 min, washed with an 
insulin-free buffer, and determined for the rate of lipolysis.  As shown in Fig. 1, 
lipolysis stimulated by low concentrations of dobutamine (0.4 and 0.8 µM) and 
isoproterenol (8 and 16 nM) was lower in the insulin-treated cells than the control cells.  
PMA attenuated lipolysis stimulated by low concentrations of dobutamine and 
isoproterenol in the control cells, but not in the insulin-treated cells.  
   The concentration of insulin (20 nM) used for pretreatment of adipocytes was 
sufficient for the total inhibition of lipolysis induced by 0.4 and 0.8 µM dobutamine in 
rat adipocytes, and washing out insulin partially restored the lipolysis (Fig. 1).  The 
restored lipolysis was again inhibited by insulin in the following assay of lipolysis.  
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Thus, insulin causes a reversible and an irreversible inhibition of lipolysis.   
   Next, adipocytes were treated with angiotensin II and α1-AR agonists, 
phenylephrine and methoxamine, and lipolysis was induced in the presence and absence 
of PMA before washing out the agents.  PMA was found to significantly attenuate 
lipolysis (Fig. 2).  Methoxamine decreased lipolysis, but PMA further reduced it.  The 
lipolysis-attenuating effect of PMA was detected in adipocytes that had been treated 
with angiotensin II, phenylephrine, and methoxamine for 30 min, and the agents were 
washed out (results not shown).  
 
3.2. Effects of PKC inhibitor and β1-AR antagonist on lipolysis  
   In the following experiments, lipolysis was stimulated by 0.8 µM dobutamine, as 
the effect of insulin was apparent (Fig. 1).  The results shown in Fig. 1 indicate that 
insulin may substitute for PMA and attenuate lipolysis.  To assess the significance of 
PKC activity, the effects of the PKCα- and β-specific inhibitor Gö 6976 (18) and the 
PKCβ-specific inhibitor LY 333531 (19) were determined in the insulin-treated 
adipocytes.  In the previous study (4), Gö 6976 was found to increase lipolysis in the 
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untreated adipocytes in the presence of PMA in a dose-dependent manner, and the 
lipolysis-attenuating effect of PMA disappeared in the presence of 0.3−3 µM Gö 6976.  
Similarly, the effect of PMA was suppressed by LY 333531 at concentrations of 0.5 µM 
or more (results not shown).  Fig. 3 shows that lipolysis in the insulin-treated cells is 
increased by 3 µM Gö 6976 much more than that in the control cells, resulting in a 
comparable level to the control.  LY 333531 at concentrations of 0.5 µM or more 
increased lipolysis in the insulin-treated cells to the control levels (Fig. 3). 
   The β1-AR antagonist CGP 20712A greatly decreased lipolysis induced by 
dobutamine in both control and insulin-treated cells, and abolished the difference in the 
rate of lipolysis between two cell preparations (Fig. 4).  The lipolysis-attenuating effect 
of PMA in the control cells as well as the increase of lipolysis by Gö 6976 in the 
insulin-treated cells were not found in the presence of CGP 20712A.  
 
3.3. Effects of wortmannin on the lipolysis-attenuating effect of PMA 
   Biological actions of insulin in the adipose tissues are mediated by the cell-surface 
receptor with intrinsic tyrosine kinase activity.  One of the immediate targets of the 
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insulin receptor is the insulin-receptor substrates (IRSs), and phosphorylation of IRSs 
on specific tyrosines creates binding sites for src homology-2 (SH2) domain-containing 
proteins, including PI3K (10, 20).  Recruitment and activation of PI3K initiates a 
series of events leading to biological actions of insulin (9, 10, 20).  Wortmannin, a 
PI3K inhibitor (21), inhibits many of insulin's effects on glucose and lipid metabolism 
(9, 10, 20).  In the present study, wortmannin increased lipolysis in a dose-dependent 
manner in the insulin-treated cells as well as lipolysis, to a lesser extent, in the control 
cells (Fig. 5).  With 40 nM or more wortmannin, no difference in the rate of lipolysis 
between the two preparations of cells was found.  Lipolysis in the control and 
insulin-treated cells determined in the presence of PMA also showed an upward 
tendency as the concentration of wortmannin increased.  The lipolysis-attenuating 
effect of PMA was not detectable in the insulin-treated cells in the presence of ≤8 nM 
wortmannin, but became apparent at higher concentrations, reaching a 43.7 ± 5.1% 
inhibition by PMA at 80 nM.  Inhibition of lipolysis by PMA in the control cells was 
always found within the range 42.3−49.9%, irrespective of the presence and absence of 
wortmannin. 
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3.4. Western blot analysis of PKC isoforms         
   In the previous report (4), we have shown that rat adipocytes express 
PKCα, βI, βII, δ, ε, and ζ.  PKCα, βI, and βII showed translocation from cytosol to 
membrane in response to acute treatment with PMA.  In this study, the amounts of 
membrane-bound PKC isoforms were determined before and after the treatment of 
adipocytes with 20 nM insulin for 30 min by Western blot analysis.  As shown in Fig. 
6, insulin caused slight increases of the membrane-bound PKCα, βI, and δ .  An 
increase of 19% was found in the membrane-bound PKCβII; however, this was not 
significant. 
   The data shown in Fig. 5 indicate that the active form of PKC responsible for 
antilipolysis in this study is rapidly decreased by wortmannin.  To examine this, 
adipocytes were treated with insulin followed by incubation with wortmannin for 10 
and 30 min, and the amounts of membrane-bound PKC isoforms were determined (Fig. 
6).  PKCβI and βII decreased after 10 min of treatment with wortmannin (Fig. 6).  A 
decrease of PKCδ  was found after 30 min of treatment with wortmannin.  No marked 
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change by wortmannin was found in the membrane-bound PKCα, ε , and ζ.   
 
4. Discussion 
    
   Recently, we have shown that PKC is a regulator of lipolysis induced by 
submaximally stimulating concentrations of β1-AR agonists (4).  The present study 
shows that exposure of rat adipocytes to insulin followed by washing out insulin 
decreases lipolysis induced by low concentrations of the β1-AR agonist dobutamine.  
This effect of insulin was not detected in the presence of a β1-AR antagonist CGP 
20712A.  The PKC inhibitors, Gö 6976 and LY 333531, normalized the rate of 
lipolysis in the insulin-treated cells.  PMA could not inhibit lipolysis in the 
insulin-treated cells.  Wortmannin abolished the effect of insulin.  These data indicate 
that insulin delivers an antilipolytic signal by using the activity of PKC.  Insulin also 
promotes diacylglycerol production (13, 14, 22), which may substitute for the action of 
PMA. 
   Conventional and novel PKCs after activation by diacylglycerol bind to membrane 
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through interaction with receptors of activated C-kinase (RACKs) and other 
PKC-interacting proteins (C-KIPs) for biological functions (23, 24).  In adipocytes, 
insulin promotes translocation of PKCα and β to membrane (14, 25, 26).  However, no 
consistent changes of intracellular distribution of PKCδ, ε  and ζ by insulin have been 
reported (14, 25, 26).  In this study, we found small increases in the membrane-bound 
PKCα, βI, and δ after treatment of adipocytes with 20 nM insulin for 30 min.  It is 
known that the insulin-induced translocation of the PKC isoforms is very rapid and 
transient, and the membrane-bound PKC isoforms are maximal at 2−10 min of insulin 
treatment and then decrease in a time-dependent manner (14, 25, 26).  Because of 
prolonged treatment in the present study, no marked increase of the membrane-bound 
PKC by insulin could be detected.   Even with such small increases, lipolysis in the 
insulin-treated cells apparently responded to the PKC inhibitors, but not to PMA.  
Wortmannin suppressed the effect of insulin and recovered the lipolysis-attenuating 
effect of PMA.  These data suggest that the PKC isoform responsible for antilipolysis 
was activated in the insulin-treated cells. 
   There are reports suggesting that activation and translocation of PKC by insulin are 
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insensitive to wortmannin (12, 27).  However, other studies have shown that 
wortmannin inhibits both insulin-mediated translocation of PKC (14, 28) and glucose 
uptake (14).  In this study, wortmannin inhibited the PKC-dependent antilipolysis by 
insulin and decreased the levels of PKC isoforms in the membrane fraction.  Insulin 
may acts through PI3K to activate phospholipase C and phospholipase D, leading to 
production of diacylglycerol (13, 14, 22).  Binding of diacylglycerol to PKC results in 
a high-affinity interaction of PKC with the specific membrane sites (29), which is 
essential for PKC to accomplish biological functions (23, 24).  Wortmannin has been 
shown to inhibit diacylglycerol production (14, 22).  Wortmannin does not directly 
inhibit PKC or affect translocation of PKC isoforms or glucose uptake by PMA (14, 28).  
Accordingly, wortmannin did not inhibit the effect of PMA on lipolysis in the control 
and insulin-treated adipocytes.  Translocation of PKCα, βI, and βII to membrane by 
PMA was not inhibited by wortmannin (results not shown).   
   It is well known that, upon interaction with the specific membrane sites, PKC is 
irreversibly activated and plays a role in signaling after Ca2+ and diacylglycerol have 
returned to basal levels (23).  This sustained activation of the enzyme may account for 
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the PKC-dependent antilipolysis found after washing out insulin.  Alternatively, 
insulin tightly bound to the insulin receptor, which is not immediately removed by 
washing with an insulin-free buffer (30, 31), may sustain signaling for the activation of 
PKC.  Adipocytes that are treated with insulin followed by washing out insulin still 
show the acute effects of insulin (30, 31).  Insulin, present in the incubation mixture, 
provokes a prolonged increase of phosphatidylinositol 3,4,5-triphosphate (PIP3), a PI3K 
by product, in adipocytes that persists at least for 1 h with no marked decrease (32, 33), 
which contrasts with a rapid and transient increase of PIP3 by epidermal growth factor 
(EGF) (32).         
   LY 333531 exhibits 40-fold or more selectivity for inhibition of PKCβ compared 
with PKCα, δ, ε , and ζ (19).  In cultured cells, LY333531 inhibits the PKCβ-mediated 
pathway with IC50 values of about 0.2 µM (34, 35).  However, even at 10 µM, LY 
333531 does not inhibit PKCδ in mouse adipocytes (36).  The fact that the effect of 
insulin is inhibited by 0.5 µM LY 333531 in the present study might suggest an 
involvement of the activity of PKCβ in the antilipolytic pathway.  Further studies are 
in progress to identify the PKC isoform responsible for antilipolysis.    
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   For full activation, PKB is phosphorylated at two sites by 
3-phosphoinositide-dependent kinase-1 (PDK1) and PDK2 (37).  Activation and 
translocation of PDK1 and PDK2 depend on PIP3.  Recently, PKCβII was shown to act 
as a PDK2 activity in some cases for activation of the catalytic domain of PKB (38).  
Thus, it is possible that PKCβII stimulated by insulin activates PKB, which then causes 
phosphorylation and activation of PDE3B.  To assess this possibility, the effect of a 
PDE3B inhibitor cilostamide (10) on the lipolysis-attenuating effect of PMA was 
determined.  In the untreated adipocytes, the effect of PMA was clearly detected in the 
presence of cilostamide (4).  Cilostamide at a concentration of 1 µM increased 
lipolysis in the insulin-treated adipocytes to a level higher than the control, although the 
mechanism is unclear.  Moreover, addition of PMA to the mixture containing 
cilostamide decreased lipolysis with a 29.2 ± 3.6 % inhibition (mean ± SEM, p < 0.01, n 
= 6).  The results suggest that rat adipocytes possess a PKC-dependent antilipolytic 
pathway, which is independent of the PDE3B activity.  
   In contrast to the results obtained with insulin, angiotensin II and α1-AR agonists 
failed to affect the lipolysis-attenuating effect of PMA, though the angiotensin II 
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receptor and α1-AR are coupled with activation of PKC (15-17).  Stimulation of 
α1-AR by norepinephrine results in translocation of PKCδ and ε to membrane (15).  
However, lipolysis induced by norepinephrine was clearly decreased by PMA (4).  At 
present, no evidence suggesting that stimulation of angiotensin II receptor or α1-AR 
induces PKC-dependent antilipolysis has been obtained.   
   The β1-AR is the dominating lipolytic AR subtype in rat adipocytes and responds to 
low plasma concentrations of norepinephrine (5).  Adipocytes from transgenic mice 
overexpressing β1-AR show an increased sensitivity of lipolytic response to 
isoproterenol and dobutamine, which may be important for preventing diet-induced 
obesity (39).  The present study indicates that insulin-mediated PKC signaling 
regulates the sensitivity of lipolysis to low concentrations of the β1-AR agonist.  In 
contrast to the reversible inhibition mediated by other effector molecules, 
PKC-dependent antilipolysis is active even after washing out insulin.  These results 
suggest a unique role for PKC signaling in the metabolism of triglycerides.    
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Figure Legends 
 
Fig. 1  Effects of PMA on dobutamine- and isoproterenol-stimulated lipolysis.  The 
isolated adipocytes were treated without (control) and with 20 nM insulin for 30 min.  
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The cells were washed with an insulin-free buffer, and mixed with increasing 
concentrations of dobutamine (A) and isoproterenol (B) in the presence () and 
absence ( ) of 0.8 µM PMA.  After being incubated at 37ºC for 20 min, the amount 
of released glycerol was determined.  The results were expressed as mean values ± 
SEM of ten (A) and four (B) experiments.  * p < 0.05; ** p < 0.01; *** p < 0.001, 
compared to no PMA.  
 
Fig. 2  Effects of angiotensin II and α1-AR agonist on the lipolysis-attenuating effect 
of PMA.  The isolated adipocytes were incubated in buffer A in the absence (None) 
and presence of 1 µM angiotensin II (AngII), 10 µM phenylephrine (Phe), and 10 µM 
methoxamine (Methox) at 37ºC for 30 min.  Then, the mixtures were added 0.8 µM 
dobutamine with and without 0.8 µM PMA.  After being incubated at 37ºC for 20 min, 
the amount of released glycerol was determined.  The results were mean values ± SEM 
of four to seven experiments, and were expressed as the percentage of the lipolytic 
activity determined without PMA or other agent.  * p < 0.05; ** p < 0.01; *** p < 
0.001, compared to no PMA.  +++ p < 0.001, compared to control (None). 
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Fig. 3  Effects of Gö 6976 and LY 333531 on lipolysis.  Lipolysis was stimulated in 
the control ( ) and insulin-treated () adipocytes by 0.8 µM dobutamine in the 
presence of Gö 6976 (A) and LY 333531 (B) at 37ºC for 20 min.  The results were 
mean values ± SEM of eight experiments, and were expressed as the percentage of the 
lipolytic activity in the control cells determined in the absence of the PKC inhibitor.  
*** p < 0.001, compared to control cells. 
 
Fig. 4  Effects of CGP 20712A on lipolysis.  The control and insulin-treated 
adipocytes were stimulated by 0.8 µM dobutamine in the presence and absence of 16 
nM CGP 20712A at 37ºC for 20 min.  The mixtures also contained 0.8 µM PMA or 3 
µM Gö 6976.  The results were mean values ± SEM of four experiments, and were 
expressed as the percentage of the lipolytic activity determined without PMA or other 
agent in the control cells.  ** p < 0.01, compared to value determined with no agent.  
 
Fig. 5  Effects of wortmannin on lipolysis.  The control (A) and insulin-treated (B) 
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adipocytes were stimulated by 0.8 µM dobutamine in the presence () and absence 
( ) of 0.8 µM PMA at 37ºC for 20 min.  The mixtures also contained wortmannin in 
the concentrations indicated.  The results were mean values ± SEM of four 
experiments, and were expressed as the percentage of the lipolytic activity determined 
without PMA or wortmannin in the control cells.  * p < 0.05; ** p < 0.01, *** p < 
0.001, compared to value determined without PMA. 
 
Fig. 6  Effects of insulin and wortmannin on membrane-bound PKC isoforms.  (A), 
the isolated adipocytes were treated without (control, C) and with 20 nM insulin (I) at 
37ºC for 30 min.  Aliquots of the insulin-treated cells were washed with an insulin-free 
buffer and incubated with 80 nM wortmannin for 10 min (I + W10) or 30 min (I + W30).  
The control-, insulin-, and insulin/wortmannin-treated cells were washed and subjected 
to preparation of the membrane fractions.  Western blot analysis was performed by 
using the antibobies specific to PKCα, βI, βII, δ, ε, and ζ as described in Materials and 
methods.  The results shown were a representative from four experiments.  (B), the 
isolated adipocytes were treated as in (A).  Immunoblots were scanned and quantified 
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by a densitometer.  The results were mean values ± SEM of four experiments, and 
were expressed as the percentage of the control cells.  * p < 0.05, ** p < 0.01, *** p < 
0.001, compared to control cells.  + p < 0.05, ++ p < 0.01, compared to insulin-treated 
cells. 
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